Biohaven Pharmaceutical announced that it enrolled the first patient in a Phase 2/3, double-blind, randomized, placebo-controlled, dose-ranging trial of intranasally administered BHV-3500 for the acute treatment of migraine. BHV-3500 is a novel, structurally distinct, third-generation calcitonin gene-related peptide receptor antagonist being developed by Biohaven. Topline efficacy and safety results are expected in the fourth quarter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.